A phase II dose-ranging study of mirabegron in patients with overactive bladder.

ABSTRACT:

Introduction and hypothesis

Mirabegron is a potent and selective β3-adrenoceptor agonist that may represent an alternative treatment option in place of antimuscarinics for patients with overactive bladder.

Methods

Patients completed a single-blinded, 2-week placebo run-in period followed by 12 weeks of randomized (n = 928) double-blinded treatment with mirabegron oral controlled absorption system (OCAS) 25, 50, 100, or 200 mg once-daily (QD), placebo or tolterodine extended release (ER) 4 mg QD. The primary endpoint was change from baseline to end-of-treatment in mean number of micturition episodes/24 h. Secondary endpoints included changes in mean volume voided per micturition; mean number of urinary incontinence, urgency urinary incontinence, and urgency episodes/24 h; sev

SUBMITTER: Chapple CR 

PROVIDER: S-EPMC3745617 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature